Literature DB >> 8823963

Impact of a mass immunization campaign against serogroup C meningococcus in the Province of Quebec, Canada.

P De Wals1, M Dionne, M Douville-Fradet, N Boulianne, J Drapeau, G De Serres.   

Abstract

A mass immunization campaign was conducted in the Province of Quebec, Canada, during the winter of 1993, following an increase in the incidence of meningococcal disease, which was mainly caused by a virulent clone of Neisseria meningitidis, serogroup C, serotype 2a. About 1.6 million doses of the polysaccharide vaccine were administered, covering 84% of the target population aged between 6 months and 20 years; the overall cost was about 25.5 million Canadian dollars. Cases notified to the regional health authorities by clinicians, hospital laboratories, and the provincial reference laboratory from January 1990 up to March 1994 have been included in the analysis. In the first year following the campaign, the incidence of the disease dropped markedly among vaccinees as well as the unvaccinated fraction of the target population, while it remained unchanged among persons aged more than 20 years. This suggests the existence of herd immunity. The overall field efficacy of the vaccine was 79%, more in teenagers and less in under-5-year-olds. A minimum of 37 cases were prevented during the first year.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8823963      PMCID: PMC2486873     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  8 in total

1.  The changing epidemiology of invasive meningococcal disease in Canada, 1985 through 1992. Emergence of a virulent clone of Neisseria meningitidis.

Authors:  C M Whalen; J C Hockin; A Ryan; F Ashton
Journal:  JAMA       Date:  1995-02-01       Impact factor: 56.272

2.  Evaluation of group C meningococcal polysaccharide vaccine in marine recruits, San Diego, California.

Authors:  L F Devine; W E Pierce; T M Floyd; S L Rhode; E A Edwards; E E Siess; R O Peckinpaugh
Journal:  Am J Epidemiol       Date:  1970-07       Impact factor: 4.897

3.  Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-70.

Authors:  R Gold; M S Artenstein
Journal:  Bull World Health Organ       Date:  1971       Impact factor: 9.408

4.  Measuring vaccine efficacy from epidemics of acute infectious agents.

Authors:  I M Longini; M E Halloran; M Haber; R T Chen
Journal:  Stat Med       Date:  1993-02       Impact factor: 2.373

5.  Emergence of a virulent clone of Neisseria meningitidis serotype 2a that is associated with meningococcal group C disease in Canada.

Authors:  F E Ashton; J A Ryan; A Borczyk; D A Caugant; L Mancino; D Huang
Journal:  J Clin Microbiol       Date:  1991-11       Impact factor: 5.948

6.  Serogroup C meningococcal outbreaks in the United States. An emerging threat.

Authors:  L A Jackson; A Schuchat; M W Reeves; J D Wenger
Journal:  JAMA       Date:  1995-02-01       Impact factor: 56.272

7.  Adverse events temporally associated with meningococcal vaccines.

Authors:  A Yergeau; L Alain; R Pless; Y Robert
Journal:  CMAJ       Date:  1996-02-15       Impact factor: 8.262

8.  Human immunity to the meningococcus. V. The effect of immunization with meningococcal group C polysaccharide on the carrier state.

Authors:  E C Gotschlich; I Goldschneider; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

  8 in total
  18 in total

1.  Evaluation of the completeness of reporting of invasive meningococcal disease.

Authors:  P Rivest; B Sagot; L Bédard
Journal:  Can J Public Health       Date:  1999 Jul-Aug

2.  Meningococcal group C conjugate vaccines.

Authors:  J Maclennan
Journal:  Arch Dis Child       Date:  2001-05       Impact factor: 3.791

3.  Genetic and antigenic analysis of invasive serogroup C Neisseria meningitidis in Canada: A decrease in the electrophoretic type (ET)-15 clonal type and an increase in the proportion of isolates belonging to the ET-37 (but not ET-15) clonal type during the period from 2002 to 2009.

Authors:  Jianwei Zhou; Frances Jamieson; Sharon Dolman; Linda Mn Hoang; Prasad Rawte; Raymond Sw Tsang
Journal:  Can J Infect Dis Med Microbiol       Date:  2012       Impact factor: 2.471

4.  Challenges to the surveillance of meningococcal disease in an era of declining incidence in montréal, Québec.

Authors:  Ruwan Ratnayake; Robert Allard
Journal:  Can J Public Health       Date:  2013-05-14

5.  Invasive meningococcal disease in Quebec, Canada, due to an emerging clone of ST-269 serogroup B meningococci with serotype antigen 17 and serosubtype antigen P1.19 (B:17:P1.19).

Authors:  Dennis K S Law; Manon Lorange; Louise Ringuette; Réjean Dion; Michel Giguère; Averil M Henderson; Jan Stoltz; Wendell D Zollinger; Philippe De Wals; Raymond S W Tsang
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

6.  Dramatic decline of serogroup C meningococcal disease incidence in Catalonia (Spain) 24 months after a mass vaccination programme of children and young people.

Authors:  L Salleras; A Domínguez; G Prats; I Parron; P Muñoz
Journal:  J Epidemiol Community Health       Date:  2001-04       Impact factor: 3.710

7.  Cost-benefit model comparing two alternative immunisation programmes against serogroup C meningococcal disease: for Quebec residents aged 2 months to 20 years.

Authors:  Carol Rancourt; Jean-Pierre Grégoire; W Simons; Alain Dostie
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 8.  Meningococcal vaccines.

Authors:  Jens U Rüggeberg; Andrew J Pollard
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

9.  Phenotypic and genetic characterization of a unique variant of serogroup C ET-15 meningococci (with the antigenic formula C:2a:P1.7,1) causing invasive meningococcal disease in Quebec, Canada.

Authors:  Raymond S W Tsang; Chao Ming Tsai; Peixuan Zhu; Louise Ringuette; Manon Lorange; Dennis K S Law
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

10.  Risk and prevention of meningococcal disease among education workers: A review.

Authors:  Philippe De Wals; Pierre Deshaies; Gaston De Serres; Bernard Duval; Lise Goulet; Bernard Pouliot; Sylvie Ricard; Maurice Poulin
Journal:  Can J Infect Dis       Date:  2004-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.